What is the PML‑RARA fusion gene and its role in acute promyelocytic leukemia?

PML::RARA Fusion Gene in Acute Promyelocytic Leukemia

The PML::RARA fusion gene is a pathognomonic chromosomal abnormality that results from the t(15;17)(q24.1;q21.2) translocation, fusing the promyelocytic leukemia (PML) gene on chromosome 15 to the retinoic acid receptor alpha (RARA) gene on chromosome 17, and is diagnostic of acute promyelocytic leukemia (APL). 1

Molecular Mechanism and Pathophysiology

The PML::RARA fusion protein acts as a potent transcriptional repressor that blocks myeloid differentiation at the promyelocytic stage:

• The fusion protein retains the DNA-binding and hormone-binding domains of RARA, allowing it to bind to retinoic acid response elements (RARE) and dimerize with retinoid X receptor protein (RXRA) 2

• PML::RARA exhibits altered transactivating properties compared to wild-type RARA, functioning as a dominant-negative regulator that interferes with normal promyelocytic differentiation 3

• The fusion protein can homodimerize, conferring the ability to regulate an expanded repertoire of genes normally not affected by RARA, thereby deregulating transcriptional control of genes involved in self-renewal and myeloid differentiation 2, 4

• Expression of PML::RARA in myeloid precursor cells causes loss of differentiation capacity under various stimuli, enhanced sensitivity to retinoic acid, and higher growth rates due to diminished apoptotic cell death 5

• The fusion protein disrupts PML nuclear bodies, contributing to the leukemogenic phenotype 4

Clinical Significance and Diagnostic Implications

APL constitutes approximately 10% of all AML cases and is distinguished by its unique biology and treatment approach:

• The median age at APL diagnosis is 44 years, younger than the median age of 67 years for general AML 1

• APL is considered a medical emergency due to severe coagulopathy and life-threatening hemorrhagic complications, particularly during induction therapy 1

• Despite its aggressive presentation, APL has been transformed from the most fatal to the most curable subtype of AML, with long-term survival exceeding 90% when properly treated 4

Molecular Variants and Detection

While PML::RARA is present in approximately 97% of APL cases, rare variant translocations exist:

• In less than 5% of cases, RARA fuses with alternative partner genes including ZBTB16, NPM1, NuMA, STAT5B, and others, causing variable sensitivity to all-trans retinoic acid (ATRA) 1

• The 2024 ACMG guidelines recommend PML::RARA fusion probes for t(15;17)(q24.1;q21.2) detection, with FISH testing initiated expeditiously when APL is suspected based on patient presentation, blast morphology, and flow cytometry results 1

• A RARA break-apart probe can detect rare variant translocations where RARA fuses with different partner genes 1

• Novel fusion variants continue to be identified, including recently reported RARA::ANKRD34C 6

Diagnostic Testing Approaches

Multiple complementary methods exist for detecting PML::RARA:

• RT-PCR detects PML::RARA fusion transcripts in 100% of cytogenetically confirmed t(15;17) cases, while RARA::PML (reciprocal fusion) is detected in only 67% of cases, suggesting the 15q+ derivative mediates leukemogenesis 7

• FISH analysis using PML::RARA fusion probes is highly specific and sensitive, less expensive and time-consuming than karyotyping, and can be performed on bone marrow or peripheral blood when blast counts are elevated 1

• Conventional karyotyping identifies t(15;17) but fails in up to 20% of cases due to poor metaphase quality and cannot detect cryptic rearrangements 1

• Flow cytometric immunobead assays can detect PML::RARA fusion proteins within 4-5 hours with sensitivity to detect at least 10% malignant cells, showing full concordance with PCR results 8

• Optical genome mapping (OGM) can characterize complex and cryptic PML::RARA rearrangements, including insertional fusions that may be missed by conventional methods 9

Therapeutic Implications

The PML::RARA fusion protein is directly targeted by specific therapies:

• ATRA and arsenic trioxide directly target PML::RARA-mediated transcriptional deregulation and protein stability, removing the differentiation block and inducing clinical remission 4

• Treatment with ATRA should be initiated immediately when APL is suspected, even before molecular confirmation, due to the medical emergency nature of the disease 1

• The chemotherapy-free approach combining ATRA and arsenic has achieved cure rates exceeding 80-90% in APL patients 1, 4

• Risk stratification based on white blood cell count (≤10,000/mcL for low/intermediate-risk vs >10,000/mcL for high-risk) guides consolidation therapy intensity 1